Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ST12
MCID: SPP011
MIFTS: 61

Suppression of Tumorigenicity 12 (ST12)

Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Suppression of Tumorigenicity 12

About this section

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 58
Prostate Adenocarcinoma 58 12 15 17
Adenocarcinoma of Prostate 6 74
Prostate Adenocarcinoma 1; Pac1 58
Prostate Adenocarcinoma 1 58
St12 58
Pac1 58

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2526
OMIM 58 601188
NCIt 51 C2919
UMLS 74 C0007112
Sources

Summaries for Suppression of Tumorigenicity 12

About this section
Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to prostatic acinar adenocarcinoma and adenocarcinoma. An important gene associated with Suppression of Tumorigenicity 12 is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Fesoterodine and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased cell migration

Description from OMIM: 601188
Sources

Related Diseases for Suppression of Tumorigenicity 12

About this section

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 prostatic acinar adenocarcinoma 32.5 AMACR KLK3 NKX3-1 TMPRSS2
2 adenocarcinoma 32.5 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
3 prostatic hyperplasia, benign 31.2 AR FOLH1 KLK3
4 transitional cell carcinoma 31.0 BRAF HRAS PTEN TP53
5 small cell carcinoma 31.0 CHGA KLK3 PTEN TP53
6 adenoma 31.0 BRAF CTNNB1 SMAD4 TP53
7 nephrogenic adenoma 30.9 AMACR KLK3 NKX3-1
8 myeloma, multiple 30.8 AKT1 BRAF HRAS IDH1 TP53
9 small cell cancer of the lung 30.6 AKT1 CHGA PIK3CA PTEN TP53
10 bladder urothelial carcinoma 30.6 AKT1 BRAF CTNNB1 HRAS IDH1 KLK3
11 squamous cell carcinoma 30.5 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
12 carcinosarcoma 30.4 CTNNB1 HRAS PIK3CA PTEN TP53
13 sarcoma 30.4 BRAF CTNNB1 HRAS PIK3CA TP53
14 lung cancer 30.4 AKT1 BRAF CHGA GSTP1 HRAS PIK3CA
15 breast adenocarcinoma 30.4 AKT1 PIK3CA PTEN SMAD4 TP53
16 glioma 30.4 BRAF IDH1 PIK3CA PTEN TP53
17 prostate cancer 30.4 AKT1 AMACR AR CHGA CTNNB1 FOLH1
18 gastrointestinal stromal tumor 30.4 AKT1 BRAF CHGA PTEN TP53
19 adenoid cystic carcinoma 30.3 AKT1 CTNNB1 HRAS IDH1 PIK3CA PTEN
20 squamous cell carcinoma, head and neck 30.2 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
21 breast cancer 29.9 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
22 lymphoepithelioma-like acinar prostate adenocarcinoma 12.2
23 prostate colloid adenocarcinoma 11.8
24 prostate signet ring cell adenocarcinoma 11.2
25 adult hepatocellular carcinoma 10.6 CTNNB1 PIK3CA TP53
26 rare adenocarcinoma of the breast 10.6 AKT1 PIK3CA TP53
27 prostate transitional cell carcinoma 10.6 CTNNB1 KLK3 PIK3CA
28 submandibular gland cancer 10.6 KLK3 TP53
29 prostate adenoid cystic carcinoma 10.6 HRAS KLK3 PIK3CA
30 female reproductive endometrioid cancer 10.6 CTNNB1 PTEN TP53
31 anal squamous cell carcinoma 10.6 AKT1 PIK3CA TP53
32 spitz nevus 10.6 BRAF HRAS TP53
33 thyroid hurthle cell adenoma 10.6 PIK3CA PTEN
34 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 PIK3CA PTEN TP53
35 serous cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
36 cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
37 proteus syndrome 10.6 AKT1 PIK3CA PTEN
38 nevus of ota 10.6 BRAF TP53
39 gliomatosis cerebri 10.6 IDH1 PTEN TP53
40 prostate squamous cell carcinoma 10.6 HRAS KLK3 TP53
41 malignant ovarian surface epithelial-stromal neoplasm 10.6 AKT1 HRAS PIK3CA TP53
42 ovary epithelial cancer 10.6 AKT1 HRAS PIK3CA TP53
43 ovary adenocarcinoma 10.6 HRAS PIK3CA TP53
44 female urethral cancer 10.6 CHGA KLK3
45 intestinal benign neoplasm 10.6 CTNNB1 HRAS TP53
46 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.6 AKT1 PIK3CA SMAD4
47 leopard syndrome 10.6 AKT1 BRAF HRAS
48 ovarian clear cell carcinoma 10.6 PIK3CA PTEN TP53
49 urethra adenocarcinoma 10.6 AMACR KLK3 SMAD4
50 peutz-jeghers syndrome 10.6 CTNNB1 PTEN SMAD4 TP53

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12
Sources

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

About this section

Clinical features from OMIM:

601188

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.93 BRAF CHGA CTNNB1 HRAS IDH1 KLK3
2 Decreased cell migration GR00055-A-1 9.72 AKT1 BRAF CTNNB1 HRAS PIK3CA
3 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 GSTP1 KLK3 PIK3CA PTEN TP53
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
5 Increased cell migration GR00055-A-3 8.92 BRAF CTNNB1 HRAS PIK3CA

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 AKT1 AMACR AR BRAF CHGA CTNNB1
2 growth/size/body region MP:0005378 10.4 AKT1 AMACR AR BRAF CHGA CTNNB1
3 mortality/aging MP:0010768 10.4 AKT1 AMACR AR BRAF CHGA CTNNB1
4 endocrine/exocrine gland MP:0005379 10.38 AKT1 AR BRAF CHGA CTNNB1 HRAS
5 behavior/neurological MP:0005386 10.35 AKT1 AR BRAF CTNNB1 HRAS NKX3-1
6 cardiovascular system MP:0005385 10.34 AKT1 AR BRAF CHGA CTNNB1 HRAS
7 cellular MP:0005384 10.33 AKT1 AR BRAF CTNNB1 KLF6 NKX3-1
8 embryo MP:0005380 10.32 AKT1 AR BRAF CTNNB1 KLF6 NKX3-1
9 integument MP:0010771 10.24 AKT1 AR BRAF CTNNB1 HRAS KLF6
10 neoplasm MP:0002006 10.2 AKT1 AR BRAF CTNNB1 HRAS NKX3-1
11 digestive/alimentary MP:0005381 10.19 AR BRAF CTNNB1 HRAS NKX3-1 PTEN
12 nervous system MP:0003631 10.17 AKT1 AR BRAF CHGA CTNNB1 HRAS
13 adipose tissue MP:0005375 10.16 AKT1 AMACR AR BRAF PIK3CA PTEN
14 liver/biliary system MP:0005370 10.16 AKT1 AMACR AR BRAF CTNNB1 KLF6
15 muscle MP:0005369 10.13 AKT1 AR BRAF CHGA CTNNB1 PIK3CA
16 limbs/digits/tail MP:0005371 10.07 AR BRAF CTNNB1 NKX3-1 PTEN SMAD4
17 normal MP:0002873 10.02 AKT1 AR BRAF CTNNB1 HRAS PTEN
18 reproductive system MP:0005389 9.93 AKT1 AR BRAF CHGA CTNNB1 KLF6
19 no phenotypic analysis MP:0003012 9.88 CHGA CTNNB1 HRAS NKX3-1 PIK3CA TP53
20 renal/urinary system MP:0005367 9.86 AR BRAF CHGA CTNNB1 HRAS PTEN
21 pigmentation MP:0001186 9.72 AR BRAF CTNNB1 PTEN TP53
22 respiratory system MP:0005388 9.61 AKT1 BRAF CTNNB1 HRAS IDH1 PTEN
23 skeleton MP:0005390 9.36 AKT1 AR BRAF CTNNB1 HRAS IDH1
Sources

Drugs & Therapeutics for Suppression of Tumorigenicity 12

About this section

Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
6 Muscarinic Antagonists Phase 4
7 Cholinergic Agents Phase 4
8 Cholinergic Antagonists Phase 4
9 Central Nervous System Depressants Phase 4
10 Diuretics, Potassium Sparing Phase 4,Not Applicable
11 Sodium Channel Blockers Phase 4,Not Applicable
12 Anti-Arrhythmia Agents Phase 4
13 Anesthetics, Local Phase 4,Phase 2
14 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
15
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
16
Bicalutamide Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90357-06-5 2375 56069
17
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
18
Goserelin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 65807-02-5 5311128 47725
19
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
20
Flutamide Approved, Investigational Phase 3,Phase 2,Phase 1 13311-84-7 3397
21
Testosterone undecanoate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
22
Methyltestosterone Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
23
Testosterone enanthate Approved Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
24
Testosterone Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0, 481-30-1 10204 6013
25
Estramustine Approved, Investigational Phase 3,Phase 1,Phase 2 2998-57-4 259331 18140
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
27
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
28
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
29
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
30
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
31
Norepinephrine Approved Phase 3 51-41-2 439260
32
Leuprolide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53714-56-0 657181 3911
33
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
34
Polyestradiol phosphate Approved Phase 3,Phase 2 28014-46-2
35
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
36
Nilutamide Approved, Investigational Phase 3,Phase 2,Phase 1 63612-50-0 4493
37
Ketoconazole Approved, Investigational Phase 3,Phase 2,Phase 1 65277-42-1 47576
38
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754
39
Vinblastine Approved Phase 3,Phase 2 865-21-4 241903 13342
40
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
41
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-03-3
42
Buserelin Approved, Investigational Phase 3,Phase 2,Phase 1 57982-77-1
43
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 69-72-7 338
44
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
45
Cefazolin Approved Phase 3 25953-19-9 33255 656510
46
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
47
Glycolic acid Approved, Investigational Phase 3 79-14-1 757
48
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
50
Diethylstilbestrol Approved, Investigational Phase 3 56-53-1 448537 3054

Interventional clinical trials:

(show top 50) (show all 657)
# Name Status NCT ID Phase Drugs
1 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Active, not recruiting NCT01661166 Phase 4 Fesoterodine
2 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
3 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3 Docetaxel + hormonal treatment (LH-RH agonist);Hormonal treatment (LH-RH agonist)
4 Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer Unknown status NCT00363285 Phase 3 cyproterone acetate
5 Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer Unknown status NCT00104715 Phase 3 antiandrogen therapy;docetaxel;goserelin acetate
6 Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00063882 Phase 3
7 Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Unknown status NCT00376792 Phase 3 docetaxel
8 Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer Unknown status NCT00796458 Phase 3 docetaxel;releasing hormone agonist therapy
9 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Unknown status NCT00084552 Phase 3
10 Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00003734 Phase 3 flutamide;triptorelin
11 Androgen Deprivation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00110162 Phase 3 antiandrogen therapy;releasing hormone agonist therapy
12 Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
13 Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer Active, not recruiting NCT02175212 Phase 3 Short term androgen deprivation;Long term androgen deprivation
14 Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate Active, not recruiting NCT01444820 Phase 3
15 Prostate Adenocarcinoma TransCutaneous Hormones Recruiting NCT00303784 Phase 3 Goserelin;Estradiol
16 Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone Active, not recruiting NCT00223145 Phase 3 Androgen blockade
17 Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI Enrolling by invitation NCT03404648 Phase 3 C-11 choline PET tracer;Gadobutrol
18 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer Recruiting NCT02624518 Phase 2, Phase 3 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
19 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
20 Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer Recruiting NCT03367702 Phase 3
21 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery Recruiting NCT02678351 Phase 2, Phase 3 gallium Ga 68-PSMA
22 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed NCT00002855 Phase 3 Bicalutamide;Doxorubicin hydrochloride;Estramustine Phosphate Sodium;Flutamide;Ketoconazole;Nilutamide;Therapeutic Hydrocortisone;Vinblastine
23 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002597 Phase 3 flutamide;Zoladex;Lupron
24 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed NCT00002633 Phase 3 bicalutamide;buserelin;flutamide;goserelin;leuprolide acetate;nilutamide
25 Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer Terminated NCT00651326 Phase 3 bicalutamide;buserelin;flutamide;goserelin;leuprolide acetate;Docetaxel
26 Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer Completed NCT00003607 Phase 3
27 Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Recruiting NCT03070886 Phase 2, Phase 3 Bicalutamide;Docetaxel;Flutamide;Goserelin Acetate;Leuprolide Acetate;Nilutamide
28 Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Recruiting NCT03686683 Phase 3
29 Muscadine Plus (MPX) In Men With Prostate Cancer Recruiting NCT03535675 Phase 3 Muscadine Plus;Placebos
30 Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer Recruiting NCT03327662 Phase 3
31 HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer. Recruiting NCT02258087 Phase 2, Phase 3
32 Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Completed NCT00065442 Phase 3
33 External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer Terminated NCT01603420 Phase 2, Phase 3 Luteinizing hormone-releasing hormone (LHRH);Docetaxel
34 Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Recruiting NCT01492972 Phase 3 Androgen Suppression Therapy
35 Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients Recruiting NCT02303327 Phase 3 Androgen deprivation therapy
36 Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer Recruiting NCT01230866 Phase 3
37 A Study of Leuprolide to Treat Prostate Cancer Completed NCT00626431 Phase 3 Leuprolide acetate - Formulation A;Leuprolide acetate - Formulation B
38 Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer Recruiting NCT03862170 Phase 3 Ciprofloxacin;Cefazolin
39 Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer Completed NCT00394511 Phase 3
40 Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer Active, not recruiting NCT03274687 Phase 3
41 A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse Recruiting NCT01952223 Phase 3 Cabazitaxel
42 Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer Completed NCT01697384 Phase 3 histrelin acetate
43 Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Completed NCT01394263 Phase 3 Histrelin hydrogel implant;Zoladex goserelin implant
44 Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Completed NCT00182052 Phase 3 Rosiglitazone
45 Hormone Therapy in Treating Patients With Advanced Prostate Cancer Completed NCT00003026 Phase 3 bicalutamide;flutamide;triptorelin
46 Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer Completed NCT00657904 Phase 3 Bicalutamide;Placebo
47 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Recruiting NCT03739684 Phase 3 18F-DCFPyL
48 Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002760 Phase 3 ketoconazole;therapeutic hydrocortisone
49 Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer Completed NCT00067015 Phase 3 bicalutamide;goserelin acetate
50 Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00027859 Phase 3 docetaxel;estramustine phosphate sodium;ketoconazole;therapeutic hydrocortisone

Search NIH Clinical Center for Suppression of Tumorigenicity 12

Sources

Genetic Tests for Suppression of Tumorigenicity 12

About this section
Sources

Anatomical Context for Suppression of Tumorigenicity 12

About this section

MalaCards organs/tissues related to Suppression of Tumorigenicity 12:

42
Prostate, Bone, Lymph Node, Brain, Testes, Skin, Thyroid
Sources

Publications for Suppression of Tumorigenicity 12

About this section

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 646)
# Title Authors Year
1
Nonylphenol acts on prostate adenocarcinoma cells via estrogen molecular pathways. ( 31108418 )
2019
2
Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma. ( 31035489 )
2019
3
Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. ( 30893781 )
2019
4
Periesophageal Lymph Node Metastasis of Prostate Adenocarcinoma From Liver Transplant Donor. ( 30840603 )
2019
5
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase III, Single Institution Randomized Clinical Trial. ( 30836166 )
2019
6
Integrative analysis of cancer driver genes in prostate adenocarcinoma. ( 30720096 )
2019
7
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma. ( 30729055 )
2019
8
PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool. ( 30656716 )
2019
9
Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT. ( 30371597 )
2019
10
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. ( 30293922 )
2019
11
An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma. ( 30257047 )
2019
12
Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (68Ga-PSMA and 18F-FDG): Potential Clinical Utility in Therapeutic Decision Making and Treatment Monitoring. ( 30139889 )
2019
13
Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. Eur Urol Oncol. In press: Primum Non Nocere: Adding Hormone Therapy to Early Salvage Radiotherapy Makes the Physician Feel Better, But Does It Help the Patient? ( 31100255 )
2018
14
Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN. ( 30774680 )
2018
15
Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed. ( 30557524 )
2018
16
Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report. ( 30470124 )
2018
17
Comparison of hock- and footpad-injection as a prostate adenocarcinoma model in rats. ( 30400793 )
2018
18
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma. ( 30273204 )
2018
19
The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. ( 30217630 )
2018
20
Prognostic value and potential function of splicing events in prostate adenocarcinoma. ( 30221674 )
2018
21
Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma. ( 30195637 )
2018
22
Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? ( 30135630 )
2018
23
Nontoxic Glucomoringin-Isothiocyanate (GMG-ITC) Rich Soluble Extract Induces Apoptosis and Inhibits Proliferation of Human Prostate Adenocarcinoma Cells (PC-3). ( 30150582 )
2018
24
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. ( 30108594 )
2018
25
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. ( 30061057 )
2018
26
Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma. ( 29984337 )
2018
27
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. ( 29992241 )
2018
28
Coexisting prostate adenocarcinoma with multiple myeloma: A rare case report. ( 30004075 )
2018
29
Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. ( 29945238 )
2018
30
Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in 68Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma? ( 29962715 )
2018
31
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. ( 29976500 )
2018
32
Testicular Metastasis in Prostate Adenocarcinoma: a Rare and Incidental Diagnosis on Histopathology. ( 29887721 )
2018
33
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. ( 29891491 )
2018
34
An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population ( 29938471 )
2018
35
Quantification of the heterogeneity of cytokeratin 18 immunoexpression in prostate adenocarcinoma and normal prostate: Global and local features. ( 29863745 )
2018
36
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. ( 29761076 )
2018
37
Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B. ( 29530270 )
2018
38
δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. ( 29121168 )
2018
39
Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. ( 29254782 )
2018
40
The expression of p-mTOR and COUP-TFII correlates with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma. ( 29544697 )
2018
41
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. ( 28716144 )
2017
42
Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma. ( 27527400 )
2017
43
Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. ( 28107606 )
2017
44
Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73. ( 28108149 )
2017
45
Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73. ( 28111115 )
2017
46
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? ( 28191651 )
2017
47
Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. ( 28216940 )
2017
48
Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review. ( 28352499 )
2017
49
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. ( 28375169 )
2017
50
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
Sources

Variations for Suppression of Tumorigenicity 12

About this section

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

6 (show top 50) (show all 374)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
21 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
23 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
24 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
25 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
28 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
29 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
30 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
31 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
32 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
33 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
34 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
36 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
37 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
38 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
43 BRAF NM_004333.5(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
44 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
46 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
47 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
48 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
50 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
Sources

Expression for Suppression of Tumorigenicity 12

About this section
Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.
Sources

Pathways for Suppression of Tumorigenicity 12

About this section

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 38
Show member pathways
 13.06 AKT1 CTNNB1 HRAS PIK3CA PTEN TP53
2
Human cytomegalovirus infection 38
Show member pathways
 13.04 AKT1 CTNNB1 HRAS PIK3CA PTEN SMAD4
3
TNFR1 Pathway 65
Show member pathways
 13.02 AKT1 CTNNB1 HRAS PIK3CA PTEN TP53
4
Focal Adhesion 1 38
Show member pathways
 12.97 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
5
Beta-Adrenergic Signaling 65
Show member pathways
 12.86 AKT1 BRAF CTNNB1 HRAS KLK3
6
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.84 AKT1 BRAF HRAS PIK3CA PTEN
7
Ras signaling pathway 38
Show member pathways
 12.79 AKT1 BRAF CTNNB1 HRAS PIK3CA
8
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.79 AKT1 HRAS PIK3CA PTEN TP53
9
Glioma 38
Show member pathways
 12.77 AKT1 BRAF HRAS PIK3CA PTEN TP53
10
Development HGF signaling pathway 23
Show member pathways
 12.76 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
11
Gastric cancer 38
Show member pathways
 12.75 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
12
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.74 AKT1 CTNNB1 HRAS PIK3CA PTEN
13
Immune response IL-23 signaling pathway 23
Show member pathways
 12.66 AKT1 CTNNB1 HRAS PIK3CA TP53
14
ErbB signaling pathway 1 38
Show member pathways
 12.66 AKT1 BRAF HRAS PIK3CA TP53
15
MicroRNAs in cancer 38
12.6 HRAS PIK3CA PTEN SLC45A3 TP53
16
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.58 AKT1 BRAF HRAS PIK3CA PTEN TP53
17
Development EGFR signaling pathway 23
Show member pathways
 12.57 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
18
Apoptosis Pathway 73
Show member pathways
 12.52 AKT1 CTNNB1 HRAS PIK3CA TP53
19
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.48 AKT1 HRAS PIK3CA TP53
20
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.48 AKT1 BRAF CTNNB1 HRAS PIK3CA
21
Development IGF-1 receptor signaling 23
Show member pathways
 12.47 AKT1 HRAS PIK3CA PTEN TP53
22
B cell receptor signaling pathway (KEGG) 38
Show member pathways
 12.46 AKT1 BRAF HRAS PIK3CA PTEN
23
Pathways in cancer 38
12.46 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
24
Human T-cell leukemia virus 1 infection 38
12.42 AKT1 CTNNB1 HRAS PIK3CA SMAD4 TP53
25
Oocyte meiosis 38
Show member pathways
 12.41 AKT1 AR BRAF PIK3CA
26
Development A3 receptor signaling 23
Show member pathways
 12.38 AKT1 CTNNB1 HRAS PIK3CA
27
B Cell Receptor Signaling Pathway (sino) 68
Show member pathways
 12.38 AKT1 HRAS PIK3CA PTEN
28
Toll Comparative Pathway 65
Show member pathways
 12.36 AKT1 HRAS PIK3CA TP53
29
Proteoglycans in cancer 38
12.33 AKT1 BRAF CTNNB1 HRAS PIK3CA TP53
30
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.31 AKT1 BRAF HRAS TP53
31
Colorectal Cancer Metastasis 65
12.27 AKT1 BRAF CTNNB1 SMAD4 TP53
32
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.27 AKT1 BRAF HRAS PIK3CA PTEN TP53
33
EGF/EGFR Signaling Pathway 1
12.26 AKT1 BRAF HRAS PTEN
34
Kit receptor signaling pathway 1
Show member pathways
 12.25 AKT1 HRAS PIK3CA PTEN
35
Cellular senescence (KEGG) 38
12.25 AKT1 HRAS PIK3CA PTEN TP53
36
mTOR Pathway 73
Show member pathways
 12.25 AKT1 BRAF HRAS PIK3CA TP53
37
NGF Pathway 65
Show member pathways
 12.22 AKT1 BRAF HRAS TP53
38
AKT Signaling Pathway 68
12.22 AKT1 HRAS PIK3CA PTEN TP53
39
Development EGFR signaling via small GTPases 23
Show member pathways
 12.21 AKT1 HRAS PIK3CA PTEN
40
Longevity regulating pathway 38
Show member pathways
 12.21 AKT1 HRAS PIK3CA TP53
41
Endometrial cancer 38
Show member pathways
 12.18 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
42
Fluid shear stress and atherosclerosis 38
12.17 AKT1 CTNNB1 GSTP1 PIK3CA TP53
43
Signaling pathways regulating pluripotency of stem cells 38
12.16 AKT1 CTNNB1 HRAS PIK3CA SMAD4
44
TGF-beta Signaling Pathway (WikiPathways) 1
12.15 AKT1 KLF6 SMAD4 TP53
45
Integrated Breast Cancer Pathway 1
12.14 AKT1 AR BRAF CTNNB1 PTEN SMAD4
46
Autophagy - animal 38
12.13 AKT1 HRAS PIK3CA PTEN
47
MAPK Pathway 73
Show member pathways
 12.11 AKT1 BRAF PIK3CA TP53
48
Development A2B receptor- action via G-protein alpha s 23
Show member pathways
 12.11 AKT1 BRAF CTNNB1 HRAS PIK3CA
49
FoxO signaling pathway 38
Show member pathways
 12.11 AKT1 BRAF HRAS PIK3CA PTEN SMAD4
50
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 12.08 AKT1 AR CTNNB1 HRAS KLK3 PIK3CA
Sources

GO Terms for Suppression of Tumorigenicity 12

About this section

Cellular components related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.4 AKT1 AMACR AR BRAF CTNNB1 GSTP1

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 AKT1 BRAF CTNNB1 GSTP1 PTEN TP53
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 AR CTNNB1 HRAS KLF6 NKX3-1
3 protein deubiquitination GO:0016579 9.93 AR PTEN SMAD4 TP53
4 negative regulation of gene expression GO:0010629 9.93 AKT1 CTNNB1 HRAS NKX3-1
5 positive regulation of cell proliferation GO:0008284 9.93 AKT1 AR CTNNB1 HRAS NKX3-1 PTEN
6 positive regulation of transcription, DNA-templated GO:0045893 9.87 AKT1 AR CTNNB1 KLF6 NKX3-1 SMAD4
7 negative regulation of cell proliferation GO:0008285 9.8 AR CTNNB1 HRAS NKX3-1 PTEN SMAD4
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 BRAF PIK3CA
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.77 GSTP1 PTEN SMAD4
10 cellular response to drug GO:0035690 9.76 BRAF NKX3-1 TP53
11 negative regulation of epithelial cell proliferation GO:0050680 9.75 AR NKX3-1 PTEN
12 negative regulation of neuron death GO:1901215 9.72 AKT1 CHGA CTNNB1
13 androgen receptor signaling pathway GO:0030521 9.71 AR CTNNB1 NKX3-1
14 cellular response to hypoxia GO:0071456 9.71 AKT1 NKX3-1 PTEN TP53
15 cellular response to nerve growth factor stimulus GO:1990090 9.65 AKT1 BRAF PTEN
16 cellular response to steroid hormone stimulus GO:0071383 9.64 AR NKX3-1
17 seminiferous tubule development GO:0072520 9.62 AR SMAD4
18 anoikis GO:0043276 9.61 AKT1 PIK3CA
19 negative regulation of cell size GO:0045792 9.61 AKT1 PTEN
20 positive regulation of glucose metabolic process GO:0010907 9.6 AKT1 SLC45A3
21 prostate gland growth GO:0060736 9.57 AR PTEN
22 regulation of axon regeneration GO:0048679 9.56 BRAF PTEN
23 cellular response to decreased oxygen levels GO:0036294 9.52 AKT1 PTEN
24 epithelial cell differentiation involved in prostate gland development GO:0060742 9.51 AR CTNNB1
25 cell proliferation GO:0008283 9.5 AKT1 AR CTNNB1 HRAS PTEN SMAD4
26 protein kinase B signaling GO:0043491 9.46 AKT1 NKX3-1 PIK3CA PTEN
27 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.43 AR CTNNB1
28 positive regulation of gene expression GO:0010628 9.23 AKT1 AR BRAF CTNNB1 HRAS NKX3-1

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 AR KLF6 NKX3-1 SMAD4 TP53
2 transcription regulatory region DNA binding GO:0044212 9.62 AR NKX3-1 SMAD4 TP53
3 protein kinase binding GO:0019901 9.55 AKT1 CTNNB1 GSTP1 PTEN TP53
4 I-SMAD binding GO:0070411 9.37 CTNNB1 SMAD4
5 enzyme binding GO:0019899 9.35 AKT1 AR CTNNB1 PTEN TP53
6 RNA polymerase II transcription factor binding GO:0001085 8.92 AR CTNNB1 SMAD4 TP53
Sources

Sources for Suppression of Tumorigenicity 12

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....